Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Integra Lifesciences Holdings Corp (NASDAQ: IART) closed at $13.04 in the last session, up 0.31% from day before closing price of $13.0. In other words, the price has increased by $0.31 from its previous closing price. On the day, 0.65 million shares were traded. IART stock price reached its highest trading level at $13.41 during the session, while it also had its lowest trading level at $12.915.
Ratios:
We take a closer look at IART’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 1.93 whereas as Long-Term Debt/Eq ratio is at 1.88.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 05 ’25 when GRAVES JEFFREY A bought 9,000 shares for $11.35 per share. The transaction valued at 102,150 led to the insider holds 41,086 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 1015956736 and an Enterprise Value of 2755558144. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 0.98. Its current Enterprise Value per Revenue stands at 1.677 whereas that against EBITDA is 8.643.
Stock Price History:
The Beta on a monthly basis for IART is 1.02, which has changed by -0.4011976 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $27.13, while it has fallen to a 52-week low of $10.87. The 50-Day Moving Average of the stock is -1.89%, while the 200-Day Moving Average is calculated to be -11.31%.
Shares Statistics:
According to the various share statistics, IART traded on average about 1.04M shares per day over the past 3-months and 834860 shares per day over the past 10 days. A total of 77.83M shares are outstanding, with a floating share count of 65.88M. Insiders hold about 15.42% of the company’s shares, while institutions hold 93.05% stake in the company. Shares short for IART as of 1764288000 were 6653021 with a Short Ratio of 6.38, compared to 1761868800 on 6896541. Therefore, it implies a Short% of Shares Outstanding of 6653021 and a Short% of Float of 13.900000000000002.
Earnings Estimates
A detailed examination of Integra Lifesciences Holdings Corp (IART) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.48, with high estimates of $0.54 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.22 and $2.17 for the fiscal current year, implying an average EPS of $2.2. EPS for the following year is $2.35, with 11.0 analysts recommending between $2.55 and $2.27.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $429.62M. It ranges from a high estimate of $434.5M to a low estimate of $426M. As of. The current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $442.64MFor the next quarter, 9 analysts are estimating revenue of $392.15M. There is a high estimate of $398.4M for the next quarter, whereas the lowest estimate is $382.01M.
A total of 10 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.63B, while the lowest revenue estimate was $1.63B, resulting in an average revenue estimate of $1.63B. In the same quarter a year ago, actual revenue was $1.61BBased on 10 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.7B and the low estimate is $1.65B.
